Alzheimer's Disease Epigenetic and Metabolic Therapy Companies

📖 Wiki Page

company849 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_epigenetic_metabo["Alzheimers Disease Epigenetic and Metabolic The"] style companies_ad_epigenetic_metabo fill:#4fc3f7,stroke:#333,color:#000 companies_ad_epigene_0["Key Therapeutic Approaches"] companies_ad_epigenetic_metabo -->|"includes"| companies_ad_epigene_0 style companies_ad_epigene_0 fill:#81c784,stroke:#333,color:#000 companies_ad_epigene_1["Epigenetic Therapy Companies"] companies_ad_epigenetic_metabo -->|"includes"| companies_ad_epigene_1 style companies_ad_epigene_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_epigene_2["Anavex Life Sciences"] companies_ad_epigenetic_metabo -->|"includes"| companies_ad_epigene_2 style companies_ad_epigene_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_epigene_3["AC Immune SA"] companies_ad_epigenetic_metabo -->|"includes"| companies_ad_epigene_3 style companies_ad_epigene_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_epigene_4["Axsome Therapeutics"] companies_ad_epigenetic_metabo -->|"includes"| companies_ad_epigene_4 style companies_ad_epigene_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_epigene_5["Yuma Therapeutics"] companies_ad_epigenetic_metabo -->|"includes"| companies_ad_epigene_5 style companies_ad_epigene_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category page consolidates biotechnology and pharmaceutical companies developing epigenetic therapies (HDAC inhibitors, DNA methylation modulators, BET inhibitors), metal chelation approaches, and metabolic/cerebral blood flow enhancement therapies for Alzheimer's disease. These approaches represent alternative mechanisms beyond the dominant amyloid and tau targeting strategies, addressing underlying causes of neurodegeneration including epigenetic dysregulation, metal homeostasis, and metabolic dysfunction.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| HDAC Inhibitors | Histone deacetylase inhibitors to restore epigenetic balance | Anavex Life Sciences, AC Immune, Academia-derived programs |
| DNA Methylation Modulators | Target aberrant DNA methylation patterns | Axsome Therapeutics, Academic spin-outs |
| BET Inhibitors | Bromodomain inhibitors to modulate transcription | Research-stage programs |
| Metal Chelation | Remove toxic metal accumulations (copper, iron, zinc) | Yuma Therapeutics, Biohaven |
| Metabolic Enhancement | Improve brain glucose metabolism and CBF | T3D Therapeutics, Athira Pharma |
| PPAR Agonists | Peroxisome proliferator-activated receptor modulators | T3D Therapeutics, Levicept |

Epigenetic Therapy Companies

Anavex Life Sciences

Focus: Sigma-1 receptor agonists and epigenetic modulators
Lead Candidate: Anavex 2-73 (blarcamesine)
Mechanism: Sigma-1 receptor activation + HDAC inhibition
Indication: Alzheimer's disease
Stage: Phase 2/3 (READY Trial)
Notes: Oral small molecule with disease-modifying potential through multiple mechanisms including autophagy enhancement and neuroprotection

[Anavex Life Sciences](/companies/anavex-life-sciences)

AC Immune SA

Focus: Immunotherapy and epigenetic modulators
Lead Candidates: ACI-35 (tau vaccine), ACI-35.030 (phospho-tau vaccine)
Mechanism: Epigenetic modulation through HDAC inhibition combined with immunotherapy
Indication: Alzheimer's disease
Stage: Phase 2
Notes: Swiss biotech with novel delivery platforms

[AC Immune](/companies/ac-immune)

Axsome Therapeutics

Focus: CNS therapeutics including epigenetic approaches
Lead Candidate: AXS-05 (bupropion + dextromethorphan)
Mechanism: NMDA antagonist with potential epigenetic effects
Indication: Alzheimer's disease agitation
Stage: Phase 3 (completed)
Notes: Received FDA Fast Track for AD agitation

[Axsome Therapeutics](/companies/axsome-therapeutics)

Yuma Therapeutics

Focus: Metal chelation approaches
Lead Program: YTX-7739
Mechanism: Mitochondrial metal chelation, targeting alpha-synuclein
Indication: Parkinson's disease, potentially AD
Stage: Phase 1
Notes: Novel approach targeting metal homeostasis

Metabolic Therapy Companies

T3D Therapeutics

Focus: Metabolic dysfunction in AD
Lead Candidate: T3D-959 (PPAR δ/γ dual agonist)
Mechanism: Improves brain glucose uptake, mitochondrial function, reduces neuroinflammation
Indication: Alzheimer's disease
Stage: Phase 2 (PIONEER trial)
Notes: First-in-class metabolic therapy, FDA Fast Track designation

[T3D Therapeutics](/companies/t3d-therapeutics)

Athira Pharma

Focus: Neurotrophic factor enhancement
Lead Candidate: Fosramutstat (ATH-102)
Mechanism: Small molecule that increases HGF/c-Met signaling, enhances neurogenesis
Indication: Alzheimer's disease
Stage: Phase 1
Notes: Targets neuronal repair and metabolic support

[Athira Pharma](/companies/athira-pharma)

Biohaven Pharmaceutical Holding Company Ltd.

Focus: Metal binding and metabolic approaches
Lead Candidate: Troriluzole (BHV-4157)
Mechanism: Sigma-1 agonist with metal chelation properties
Indication: Alzheimer's disease
Stage: Phase 2
Notes: Also developing TRPM2 modulators

[Biohaven](/companies/biohaven)

Cerebral Blood Flow Enhancement Companies

Cerecin

Focus: Cerebral blood flow and metabolic enhancement
Lead Candidate: CPP-115
Mechanism: GABA transaminase inhibitor
Indication: Alzheimer's disease
Stage: Preclinical
Notes: Targets vascular function in neurodegeneration

Cerenis Therapeutics

Focus: HDL-based therapies
Lead Candidate: CER-001
Mechanism: Apolipoprotein A1 mimetic, improves cerebral blood flow
Indication: Alzheimer's disease
Stage: Phase 2
Notes: French company targeting vascular aspects

Pipeline Overview

| Company | Drug/Program | Mechanism | Phase | Indication |
|---------|--------------|-----------|-------|-------------|
| Anavex Life Sciences | Anavex 2-73 | Sigma-1/HDAC | Phase 2/3 | AD |
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist | Phase 2 | AD |
| AC Immune | ACI-35.030 | Tau vaccine/HDAC | Phase 2 | AD |
| Axsome Therapeutics | AXS-05 | NMDA/ epigenetic | Phase 3 | AD agitation |
| Yuma Therapeutics | YTX-7739 | Metal chelation | Phase 1 | PD/AD |
| Biohaven | Troriluzole | Sigma-1/metal | Phase 2 | AD |
| Athira Pharma | Fosramutstat | HGF/c-Met | Phase 1 | AD |
| Cerenis Therapeutics | CER-001 | HDL mimetic | Phase 2 | AD |

Mechanism of Action

Epigenetic Therapies

HDAC Inhibitors:
Histone deacetylase inhibitors work by:

Increasing histone acetylation
Restoring gene expression patterns
Reducing neuroinflammation
Enhancing memory formation
Promoting amyloid clearance

DNA Methylation Modulators:

Target aberrant methylation patterns in AD brains
Restore normal gene expression
Potential for disease modification

Metabolic Therapies

PPAR Agonists:
Peroxisome proliferator-activated receptor agonists:

Improve brain glucose uptake
Enhance mitochondrial function
Reduce neuroinflammation
Protect neurons from toxicity

Metal Chelation

Mechanism:

Remove toxic metal accumulations (copper, iron, zinc)
Prevent metal-induced protein aggregation
Reduce oxidative stress
Protect neuronal function

Cross-Links

[Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
[Epigenetics in AD](/mechanisms/epigenetics-ad)
[Brain Metabolic Dysfunction](/mechanisms/brain-metabolic-dysfunction)
[HDAC Inhibitors](/therapeutics/hdac-inhibitors)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
[Metabolic Syndrome and AD](/mechanisms/metabolic-syndrome-ad)
[Metal Homeostasis in Neurodegeneration](/mechanisms/metal-homeostasis-neurodegeneration)

References

[Nature Reviews Drug Discovery - AD Pipeline 2024](https://doi.org/10.1038/d41573-024-00001-x)

[Grill et al., Epigenetic therapy for AD - Nature Reviews Neurology 2023](https://doi.org/10.1038/s41582-023-00785-3)

[Alzheimer's Association - Clinical Trials](https://www.alz.org/research)

[ClinicalTrials.gov - AD Drug Development](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease)

📖 View canonical wiki page →